Strategic Consulting Services

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Strategic Consulting Services"

Transcription

1 Services 1

2 Leadership Team Mark Levonyak President Mobile: Martin W. Lee, MD EVP, Clinical Trial Services Mobile: John Eckardt, MD Chief Medical Officer Mobile: Nora Ku, MD Sr. Medical Director Mobile: Annemieke DeMaggio, PhD VP, Scientific Affairs Mobile: Gregory Pynes, MPA, CMP Executive Director, Meetings, Branding, and Partnerships Mobile: Nicolas Kuehl VP, Business Development Mobile: DAVA Oncology, LP Four Forest Plaza Merit Drive, Suite 820 Dallas, TX

3 DAVA Scientific Services DAVA s medical oncology expertise provides a unique perspective in drug development. Click one of our services on the left to start. Scenarios & Case Studies 3

4 Tumor Compass Reference Guide Pathway Navigator Clinical & Competitive Landscapes Congress Coverage 4

5 Tumor Compass Collects prioritized information from publicly available resources Organizes relevant data into interactive format to allow for intuitive navigation Highlights clinical and competitive insights based on historical perspective and forward-looking analyses 5

6 Tumor Compass Explore the current standard of care including Line of Therapy, Key Competitors, Patient Subsets or Optimal Sequencing of Agents LOT- Key clinical trials are organized on a timeline to reflect changes in regulatory and clinical standards over time MOA- Each competitor profile includes key preclinical and clinical data; detailed summaries of ongoing trials include milestone estimates and impact analyses Patient Subsets- Reviews impact of risk stratification and histology on the treatment paradigm Click Image 6

7 Standard of Care Reference Guides Tumor-specific reference guides highlight pivotal trials that have shaped standard of care and practice patterns Examination of the objective impact and authors conclusions Customizable for all audiences Medical, marketing, training User friendly, clickable PDF, platform neutral ipad, Windows/PC, web-portal Click Image 7

8 Pathway Navigator Comprehensive overview including mutations, activation, downstream signaling Patients selection, molecular subsets and inhibition by tumor type Pathway inhibitors, clinical development and competitive landscape by company and patient segment Click Image 8

9 Clinical & Competitive Landscape To create the clinical landscape, we focus on: The current and future treatment paradigms Clinical and molecular patient segmentation Epidemiology Tumor biology Role of biomarkers Highlight regulatory strategies Provide developmental timelines of key competitors Click Image 9

10 Congress Coverage Click Image Congress coverage is a key tool to stay one step ahead of the competition This process begins with a pre-meeting benchmark analysis and congress road map of relevant data being presented The next step is comprehensive congress coverage to provide you with post-meeting analysis, commentary, and insight by DAVA s medical oncology professionals Click for Example Click Image 10

11 Disease Strategy & Portfolio Planning Clinical Development Strategies Life Cycle Management 11

12 DAVA Process Our process begins with a clinical and competitive landscape analysis, which is validated by external opinion leaders and DAVA medical experts and aligned with your key internal stakeholders. We leverage our unique strengths, oncology expertise and proprietary strategic toolbox to achieve your goals. Each project is customized to the sponsor s requests by utilizing the DAVA strategic tools outlined in the above sections. 12

13 Disease Strategy & Portfolio Planning Identify and validate relevant clinical and commercial development opportunities and competitive threats Optimize assets in development to maximize the entire disease or product portfolio Provide insight for the pipeline development & clinical trial design Click Image 13

14 Clinical Development Strategies Create a strategy to optimize clinical potential while limiting competitor impact; create product profile for key competitors Clinical development strategies address critical issues in: Trial design & feasibility Patient segmentation Unmet needs Identify key risks in the study designs and provide a strategy for their mitigation Click Image 14

15 Life Cycle Management Provide strategic insight and tactical recommendations around the design of clinical development programs to support future growth Validate the life cycle management plan with key internal stakeholders to obtain views on clinical, regulatory, and marketing aspects 15

16 Advisory Feedback War Games Qualitative Insights 16

17 Advisory Feedback Recruit academic and community experts to define treatment patterns Access to DAVA s physician database Pressure test strategies and tactics Provide clinical insight and recommendations for short and long term strategies 17

18 War Games Anticipate and react to competitors actions Respond to competitive new product entries Define competitors potential messaging and positioning Develop strategies and tactical objections to competitors messaging 18

19 Qualitative Insights 1 on 1 in depth interviews moderated by DAVA Medical Oncologists on key clinical and regulatory events Gain a deeper understanding beyond a traditional moderator Identify strengths and weaknesses of the clinical data Learn how to best communicate data and key messaging 19

20 Anticipating competitors actions and reactions to your moves may be the key determinant of success for any marketing strategy. One competitor loses exclusivity eroding category pricing, undermining your pricing strategy. Another may decide to offer new products that have the potential to completely undermine your existing strategy. Could you have anticipated such moves? How do you respond? Case Studies & Scenarios 20

21 Challenging Market Scenarios 21

22 Case Study: Strategies for Achieving Advantage Situational Analysis Company A preparing for new product launch A1 into highly competitive and crowded market. The existing agents enjoy high physician satisfaction due to their innovator status. Company A s drug A1 offers improved mechanism of action with a higher affinity for the therapeutic target resulting in moderate efficacy improvement and significant toxicity & convenience advantage. 22

23 DAVA Approach & Tools Clinical Landscape Competitor Analysis Market Overview External Validation Advisory Feedback War Games Internal Stakeholder Alignment MSL Training Tumor Compass Strategy Development Execution DAVA has developed a clinical landscape overview that includes trials that define the standard of care and the emerging competitors, including development timelines DAVA Tumor Compass provided a reservoir and quick-reference guide of up-to-date clinical information to chart the course DAVA validated & pressure tested key assumptions, clinical data, and strategies with medical experts providing internal alignment. This process ensures launch readiness is in line with clinician expectations. 23

24 Why DAVA Oncology? Our Promise To improve patient care by realizing the full potential of oncology drug development Since inception, DAVA has worked with over 30 companies, from big pharma to small biotech, on over 160 projects Our people are led by five seasoned medical oncologists with decades of clinical oncology experience, two PhDs with extensive training in oncology and two pharmaceutically-trained executives with many years of experience in the oncology space We provide strategic intelligence that is customized to fit your needs Our services can be tailored to clinical development, new product planning, or the commercial setting of your drug development We offer a wide range of services to meet your unmet needs 24

Access. Action. Insight. Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions

Access. Action. Insight. Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions Cardinal Health Specialty Solutions Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions Access Action Insight In today s increasingly competitive healthcare

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

The Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014

The Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014 The Role of Regional Medical Advisor (RMA)-Field Medical Dr. Aju Abraham Varghese Pfizer India Feb 22 nd 2014 Disclaimer The opinions expressed in this presentation are solely those of the presenter and

More information

Preparing a New Dermatologic Agent for Market Launch. March, 2011

Preparing a New Dermatologic Agent for Market Launch. March, 2011 Preparing a New Dermatologic Agent for Market Launch March, 2011 The Situation A major pharmaceutical company sought to better understand how physicians treat patients with moderate to severe psoriasis

More information

BEST PRACTICES RESEARCH

BEST PRACTICES RESEARCH 2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost

More information

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013

CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013 CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT EXECUTIVE SUMMARY April 2013 Copyright CMO Council. All Rights Reserved. 2013 ABSTRACT Change and transformation have become common occurrences if not required

More information

Medical Science Liaison (MSL): Understanding, Engaging and Interacting. Gill Logan Regional Medical Affairs Manager Takeda UK

Medical Science Liaison (MSL): Understanding, Engaging and Interacting. Gill Logan Regional Medical Affairs Manager Takeda UK Medical Science Liaison (MSL): Understanding, Engaging and Interacting Gill Logan Regional Medical Affairs Manager Takeda UK Date of upload, October 2011 Disclosures Takeda UK employee Member of the MSLA

More information

Big Data for Patients (BD4P) Program Overview

Big Data for Patients (BD4P) Program Overview Big Data for Patients (BD4P) Program Overview [Updated August 5, 2015] Proposal: Big Data for Patients (BD4P) Training Program Page 1 Background The new and emerging field of data science ( Big Data )

More information

Onboarding. Design Build Attract

Onboarding. Design Build Attract Onboarding Design Build Attract The most critical time in an executive s career is the first 100 days in a new role. Executives promoted or hired into new roles are expected to not only find their way,

More information

Multiple Myeloma (Event Driven)

Multiple Myeloma (Event Driven) Brochure More information from http://www.researchandmarkets.com/reports/2234830/ Multiple Myeloma (Event Driven) Description: The 2010 multiple myeloma (myeloma) market garnered impressive sales despite

More information

Transforming study start-up for optimal results

Transforming study start-up for optimal results Insight brief Transforming study start-up for optimal results A holistic, data-driven approach integrating technology, insights and proven processes to position clinical trials for ultimate success Up

More information

Oncology Knowledge Bulletin. Strategies in oncology: Spotlight on clinical pathways

Oncology Knowledge Bulletin. Strategies in oncology: Spotlight on clinical pathways Strategies in oncology: Spotlight on clinical pathways 2 In response to rising healthcare costs, US payors have increased efforts to control drug costs, including through step edits or discounts for contracts.

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

The registry of the future: Leveraging EHR and patient data to drive better outcomes

The registry of the future: Leveraging EHR and patient data to drive better outcomes The registry of the future: Leveraging EHR and patient data to drive better outcomes Brian J. Kelly, M.D. President, Payer and Provider Solutions, Quintiles Jason Colquitt, VP, IT, Head of RWLPR IT, Global

More information

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

Financial Data Model Standardization

Financial Data Model Standardization 2081 Business Center Dr. Irvine, CA 92612 800.215.4671 www.zendeux.com Financial Data Model Standardization A Zendeux Business Data Solutions White Paper Majd Izadian Managing Partner Contents Client:

More information

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating

More information

Is it time for a new drug development paradigm?

Is it time for a new drug development paradigm? Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and

More information

The agency perspective: What we do and how we do it

The agency perspective: What we do and how we do it The agency perspective: What we do and how we do it Tim Ryder and Olga Dai 15 July 2011 Who are we? Tim Ryder Scientific Team Leader, Darwin HC MA in Biochemistry; DPhil in Physiology 10 years of experience

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:

More information

RETHINKING DIGITAL SELLING

RETHINKING DIGITAL SELLING RETHINKING DIGITAL SELLING BEST PRACTICES FOR MAXIMIZING RESULTS AND ROI Guiding Principles For Rethinking Your Digital Selling Strategy It s been nearly four years since reps started using tablet-based

More information

The Patient Journey in High Resolution

The Patient Journey in High Resolution The Patient Journey in High Resolution Innovating for a richer understanding of the patient journey By Jackie Ilacqua Tel +1 201-574-8079 Email jackie.ilacqua@ipsos.com 1 xx-xx-xx Achieving a rich, yet

More information

Global regulatory affairs role in the biopharmaceutical industry

Global regulatory affairs role in the biopharmaceutical industry CHAPTER TWO Global affairs role in the biopharmaceutical industry 2.1 Overview 2.2 Global affairs organization 2.3 Role of global affairs 2.4 Key functions and activities 2.5 Global strategy 2.6 Global

More information

A Primer: Solving the Unique Problems of Orphan Drug Communications Programs

A Primer: Solving the Unique Problems of Orphan Drug Communications Programs A Primer: Solving the Unique Problems of Orphan Drug Communications Programs Introduction When communicating about orphan diseases and development of pharmaceuticals, it is essential to recognize the special

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

The agency perspective

The agency perspective The agency perspective 16 January 2014 Anna Palmer Scientific Services Manager Contents What is medical communications? How did I get here? Medical communications vs other agencies What do we actually

More information

White Paper. by Brian Mondry, Vice President, Integrated Strategy & Digital Solutions March 2012

White Paper. by Brian Mondry, Vice President, Integrated Strategy & Digital Solutions March 2012 White Paper Catalysts driving successful decisions in life sciences. Achieving Insights in the US Multiple Sclerosis (MS) Patient Community through a combination of traditional data research and mixed

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

Global Oil & Gas Suite

Global Oil & Gas Suite IHS ENERGY Global Oil & Gas Suite Comprehensive analysis and insight on upstream opportunities, risk, infrastructure dynamics, and downstream markets Global Oil & Gas Suite Make optimal decisions about

More information

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S PURPOSE JDRF, the world s leading non-profit organization with

More information

Oncology Spotlight Early Commercialization Case Study. Susie Newton RN, MS, AOCN, AOCNS: Senior Director Quintiles Health Management Solutions

Oncology Spotlight Early Commercialization Case Study. Susie Newton RN, MS, AOCN, AOCNS: Senior Director Quintiles Health Management Solutions Oncology Spotlight Early Commercialization Case Study Susie Newton RN, MS, AOCN, AOCNS: Senior Director Quintiles Health Management Solutions Objectives Demonstration of the need for early commercialization

More information

Technology and Expertise Add Operational Value to Medical Device Trials

Technology and Expertise Add Operational Value to Medical Device Trials Technology and Expertise Add Operational Value to Medical Device Trials Copyright 2015 Medidata Solutions. Medidata Solutions and other trademarks reserved in the US and globally. Medidata and other marks

More information

The Medical Communications Agency

The Medical Communications Agency The Medical Communications Agency Paul Hatton E U R O P E U N I T E D S T A T E S A S I A P A C I F I C Objectives What do medical communications agencies do? What might a career in medical communications

More information

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:

More information

WHAT WE DO HOW OLIVER WYMAN S HEALTH & LIFE SCIENCES TEAM DRIVES INNOVATION BY IMPLEMENTING TRANSFORMATIVE IDEAS. Oliver Wyman

WHAT WE DO HOW OLIVER WYMAN S HEALTH & LIFE SCIENCES TEAM DRIVES INNOVATION BY IMPLEMENTING TRANSFORMATIVE IDEAS. Oliver Wyman WHAT WE DO HOW OLIVER WYMAN S HEALTH & LIFE SCIENCES TEAM DRIVES INNOVATION BY IMPLEMENTING TRANSFORMATIVE IDEAS Population Health Management Oliver Wyman helped a large national retail pharmacy chain

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

Engaging Clinical Trial Sites:

Engaging Clinical Trial Sites: WHITE PAPER Engaging Clinical Trial Sites: The Role of the Clinical Trial Liaison Author: MARTIN LEE, MD Vice President, Global Scientific Affairs PRA Health Sciences Key Customers in Clinical Research

More information

MEDICAL DEVICE & DIAGNOSTICS

MEDICAL DEVICE & DIAGNOSTICS to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,

More information

Orphan Pharma: pathfinders for an increasingly specialised industry

Orphan Pharma: pathfinders for an increasingly specialised industry Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty

More information

An Introduction to Valuations

An Introduction to Valuations An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your

More information

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge

More information

Big Data An Opportunity or a Distraction? Signal or Noise?

Big Data An Opportunity or a Distraction? Signal or Noise? Big Data An Opportunity or a Distraction? Signal or Noise? Maya R. Said, Sc.D. SVP & Global Head, Oncology Policy & Market Access, Novartis 3rd International Systems Biomedicine Symposium Luxembourg, 28

More information

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second

More information

CLINICAL DEVELOPMENT OPTIMIZATION

CLINICAL DEVELOPMENT OPTIMIZATION PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP

More information

Keys to success in multi-channel marketing in Japan

Keys to success in multi-channel marketing in Japan Keys to success in multi-channel marketing in Japan Abstract In the US and Europe, we have seen a drastic decline in the number of MRs and a rapid shift towards non-traditional multi-channel marketing

More information

Pharmaceutical Sales Certificate

Pharmaceutical Sales Certificate Pharmaceutical Sales Certificate Target Audience Medical representatives Objective The objective of this program is to provide the necessary skills and knowledge needed to succeed as medical representatives.

More information

Big Data jako součást našeho života. Zdenek Panec: June, 2015

Big Data jako součást našeho života. Zdenek Panec: June, 2015 Big Data jako součást našeho života Zdenek Panec: June, 2015 Agenda Big Data talk.. Primary Big Data Scenarios Big Data as Chance & Risk SAP HANA Platform 2013 SAP AG or an SAP affiliate company. All rights

More information

Renal Cell Carcinoma (Event Driven)

Renal Cell Carcinoma (Event Driven) Brochure More information from http://www.researchandmarkets.com/reports/2365661/ Renal Cell Carcinoma (Event Driven) Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that

More information

PHARMACEUTICAL SALES MANAGEMENT

PHARMACEUTICAL SALES MANAGEMENT PHARMACEUTICAL SALES MANAGEMENT SHARPENING CUSTOMER-CENTRIC STRATEGIES TO RESTORE ACCESS AND STRENGTHEN RELATIONSHIPS PUBLICATION DATE FEB. 2014 PAGES 195 CHAPTERS 4 THE BOTTOM LINE: New regulations and

More information

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial

More information

Twelve Ways Healthcare Organizations Are Enhancing Patient Experience. A WBR Digital ebook

Twelve Ways Healthcare Organizations Are Enhancing Patient Experience. A WBR Digital ebook Twelve Ways Healthcare Organizations Are Enhancing Patient Experience A WBR Digital ebook September 2014 Introduction Table of Contents Introduction... 2 Research Findings The Institutionalization of Patient

More information

Integrated Life Cycle Patient Access Solutions that Maximize Brand ROI

Integrated Life Cycle Patient Access Solutions that Maximize Brand ROI Integrated Life Cycle Patient Access Solutions that Maximize Brand ROI August, 2013 Bob Hastings Vice President of Marketing Pharmaceutical brand marketers are facing a paradigm shift in the way they market

More information

The Role of the CRO in Effective Risk-Based Monitoring

The Role of the CRO in Effective Risk-Based Monitoring New Whitepaper The Role of the CRO in Effective Risk-Based Monitoring The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging

More information

Cautionary Statement

Cautionary Statement Cautionary Statement The following document contains certain forward-looking statements and forward-looking information, which is based on current expectations, estimates, projections, assumptions and

More information

RE AP QUE PLIC FOR IONS. Compa CPRIT RFA C 12 FORM 2. Company. p.1/17

RE AP QUE PLIC FOR IONS. Compa CPRIT RFA C 12 FORM 2. Company. p.1/17 RE AP QUE ST PLIC AT RFA C 12 FORM 2 FOR IONS Compa any Formation Awards FY 2012 Fiscal Year Award Period September 1, 2011 Augustt 31, 2012 CPRIT RFA C 12 FORM 2 (Rev 6/ /30/11) Company Formation Awards

More information

Health of Women (HoW) Program Launch: Participant Workbook

Health of Women (HoW) Program Launch: Participant Workbook Health of Women (HoW) Program Launch: Participant Workbook June 24-25, 2013 Name: Title: Affiliation /Organization: Email: Workbook completion instructions: Record your action-oriented ideas throughout

More information

HR TEAM BUSINESS PLAN 2012-2014 Page 1 of 5

HR TEAM BUSINESS PLAN 2012-2014 Page 1 of 5 HR TEAM BUSINESS PLAN 2012-2014 Page 1 of 5 VISION We stand proudly on the leading edge of innovative HR practices to make a real difference in the success of our people. MISSION Using the Guiding Beliefs

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations

More information

Stakeholder Guide 2014 www.effectivehealthcare.ahrq.gov

Stakeholder Guide 2014 www.effectivehealthcare.ahrq.gov Stakeholder Guide 2014 www.effectivehealthcare.ahrq.gov AHRQ Publication No. 14-EHC010-EF Replaces Publication No. 11-EHC069-EF February 2014 Effective Health Care Program Stakeholder Guide Contents Introduction...1

More information

P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything

P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

Specialty Pharmacy? Disclosure. Objectives Technician

Specialty Pharmacy? Disclosure. Objectives Technician Disclosure What s so SPECIAL about? I have no actual or potential conflict of interest in relation to this program/presentation. Michael DeCoske, PharmD, BCPS Associate Chief Pharmacy Officer Duke University

More information

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations

More information

Meeting Priorities of Biotech & Small Pharma Companies

Meeting Priorities of Biotech & Small Pharma Companies Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,

More information

HOT TOPICS IN IN HEALTH CARE REFORM

HOT TOPICS IN IN HEALTH CARE REFORM By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable

More information

Social Business Analytics

Social Business Analytics IBM Software Business Analytics Social Analytics Social Business Analytics Gaining business value from social media 2 Social Business Analytics Contents 2 Overview 3 Analytics as a competitive advantage

More information

Cloud Marketing: Faces in the Cloud

Cloud Marketing: Faces in the Cloud Robert Groebel September 25, 2015 Features Cloud Marketing: Faces in the Cloud Share this article: facebook twitter linkedin google Comments Email Print As the need for more informed conversations with

More information

Business process overview and due diligence checklist to assess new small business funding opportunities

Business process overview and due diligence checklist to assess new small business funding opportunities Business process overview and due diligence checklist to assess new small business funding opportunities Foundations that fund medical research increasingly have and are taking the opportunity to fund

More information

Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022

Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2152222/ Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022 Description: Xarelto (Atrial Fibrillation) Analysis and

More information

The Rising Tide of Pharmacy Benefit Cost and Complexity: A health plans roadmap to optimizing pharmacy services relationships

The Rising Tide of Pharmacy Benefit Cost and Complexity: A health plans roadmap to optimizing pharmacy services relationships The Rising Tide of Pharmacy Benefit Cost and Complexity: A health plans roadmap to optimizing pharmacy services relationships New pharmacy benefit challenges After several years of manageable pharmacy

More information

Organization and Job Profile

Organization and Job Profile Organization and Job Profile New Orleans, Louisiana Position: Reports to: Location: System Vice President for Research New Orleans, Louisiana CORPORATE BACKGROUND is a non-profit, academic, multi-specialty,

More information

Immunovaccine Inc. (TSX-V: IMV) July 2011

Immunovaccine Inc. (TSX-V: IMV) July 2011 Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities

More information

High Country Nuclear Medicine Conference Clinical Decision Support, the Good, the Bad and the Ugly Sue Bunning, Director Health Policy and Regulatory

High Country Nuclear Medicine Conference Clinical Decision Support, the Good, the Bad and the Ugly Sue Bunning, Director Health Policy and Regulatory High Country Nuclear Medicine Conference Clinical Decision Support, the Good, the Bad and the Ugly Sue Bunning, Director Health Policy and Regulatory Affairs March 2, 2015 SNMMI s History Founded in 1954

More information

The Leukemia & Lymphoma Society Strategic Plan FY 13 15

The Leukemia & Lymphoma Society Strategic Plan FY 13 15 Creating a world without blood cancers Since 1954, The Leukemia & Lymphoma Society has awarded research funding to academic investigators, medical centers and companies, to accelerate new treatments and

More information

Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion...

Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion... Contents Background and Company Performance... 3 Industry Challenges... 3 Product Family Attributes and Business Impact... 3 Conclusion... 5 Significance of Product Leadership... 6 Understanding Product

More information

BIOINFORMATICS Supporting competencies for the pharma industry

BIOINFORMATICS Supporting competencies for the pharma industry BIOINFORMATICS Supporting competencies for the pharma industry ABOUT QFAB QFAB is a bioinformatics service provider based in Brisbane, Australia operating nationwide and internationally. QFAB was established

More information

Welcome to the Launch of Biocon s Breakthrough Innovation. For Psoriasis. Treatment

Welcome to the Launch of Biocon s Breakthrough Innovation. For Psoriasis. Treatment Welcome to the Launch of Biocon s Breakthrough Innovation For Psoriasis Treatment PRESS MEET Bangalore, August 10, 2013 Autoimmune Diseases are on the Rise Globally Autoimmune Disease Segment includes

More information

Clinical Trial Supply Chain Driving Transformation for Excellence

Clinical Trial Supply Chain Driving Transformation for Excellence Clinical Trial Supply Chain Driving Transformation for Excellence October 20, 2009 2009 AMR Research, Inc. Page 1 Key Success Criteria of Life Sciences Companies Q84. What are your company s key success

More information

White Paper January 2009. Top Ten Reports in Clinical Performance Management

White Paper January 2009. Top Ten Reports in Clinical Performance Management White Paper January 2009 Top Ten Reports in Clinical Performance Management 2 Contents 3 The solution Clinical Performance Management Clinical Trail Resource Planning Reports Report #1 Clinical Trial Project

More information

The Promise and Challenge of Adaptive Design in Oncology Trials

The Promise and Challenge of Adaptive Design in Oncology Trials THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic

More information

Performance Profile. Clinical Study Physician. www.celyad.com 1

Performance Profile. Clinical Study Physician. www.celyad.com 1 Performance Profile Clinical Study Physician www.celyad.com 1 Role: Provide medical guidance and leadership throughout the development and conduct of clinical trials. You will be responsible for overseeing

More information

Whitepaper: MSL and Sales Strategies for the US Oncology Market

Whitepaper: MSL and Sales Strategies for the US Oncology Market Whitepaper: MSL and Sales Strategies for the US Oncology Market Oncology: where an expansive market opportunity interests with an extremely high cost of failure. Companies have been built, sold, and failed

More information

Driving Excellence in Implementation and Beyond The Underlying Quality Principles

Driving Excellence in Implementation and Beyond The Underlying Quality Principles SAP Thought Leadership Paper SAP Active Quality Management Driving Excellence in Implementation and Beyond The Underlying Quality Principles 2014 SAP AG or an SAP affiliate company. All rights reserved.

More information

Translating to the language of payers

Translating to the language of payers Translating to the language of payers Actuarial analyses of new drug therapies Gregory Warren, FSA, MAAA Vice President, Pharmacy Actuarial Consulting 303-714-1022 gregory.warren@optum.com 1 Why are actuaries

More information

The Missing Keys in Key Account Management: Three Questions That Can Transform Your Sales Force. Bill Coyle and Jude Konzelmann

The Missing Keys in Key Account Management: Three Questions That Can Transform Your Sales Force. Bill Coyle and Jude Konzelmann The Missing Keys in Key Account Management: Three Questions That Can Transform Your Sales Force Bill Coyle and Jude Konzelmann The Missing Keys in Key Account Management: Three Questions That Can Transform

More information

e-training Transition Project

e-training Transition Project e-training Transition Project Phase II e-training Communications Guide August 24, 2005 National Aeronautics and Space Administration Communications Guide for the Phase II e-training Transition August 24,

More information

Perspectives on Patient Recruitment

Perspectives on Patient Recruitment Webcast Perspectives on Patient Recruitment Sponsors: Presenters Moderator: Christiane Truelove Editor in Chief, R&D Directions Chris.Truelove@ubm.com Speakers: Dr. Bradley Vince, D.O., President and Medical

More information

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant 2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February

More information

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your

More information

WORKSHOP By Andre Harrell

WORKSHOP By Andre Harrell ACCOUNT BUSINESS PLANNING WORKSHOP By Andre Harrell AH2 & Beyond Consulting can tailor this workshop to meet your needs and we pride ourselves on that flexibility. The next few slides is a very abbreviated

More information

Movember Clinical Trial Award (CTA)

Movember Clinical Trial Award (CTA) Movember Clinical Trial Awards Part 1: Overview Participating Organisation (s) Funding Category Description The Movember Foundation and Prostate Cancer Foundation of Australia Movember Clinical Trial Award

More information

Voluntary Genomic Data Submissions at the U.S. FDA

Voluntary Genomic Data Submissions at the U.S. FDA Voluntary Genomic Data Submissions at the U.S. FDA International Conference on Harmonization Chicago, IL November 9-10, 9 2005 Felix W. Frueh, PhD Associate Director for Genomics Office of Clinical Pharmacology

More information

Qualification in Internal Audit Leadership (QIAL ) Exam Syllabus

Qualification in Internal Audit Leadership (QIAL ) Exam Syllabus QIAL SYLLABUS MARCH 2015 Qualification in Internal Audit Leadership (QIAL ) Exam Syllabus The QIAL assessment comprises five sections: Case study 1*: Internal Audit Leadership (3 hours and 45 minutes)

More information

Research Gamification for Quality Pharmaceutical Stakeholder Insights. White Paper. by Brian Mondry and Leah Fink March 2015

Research Gamification for Quality Pharmaceutical Stakeholder Insights. White Paper. by Brian Mondry and Leah Fink March 2015 White Paper Catalysts driving successful decisions in life sciences. Research Gamification for Quality Pharmaceutical Stakeholder Insights by Brian Mondry and Leah Fink March 2015 www.kantarhealth.com

More information